SYNERGY OF FLUCONAZOLE WITH HUMAN MONOCYTES OR MONOCYTE-DERIVED MACROPHAGES FOR KILLING OF CANDIDA SPECIES

被引:22
作者
GARCHA, UK
BRUMMER, E
STEVENS, DA
机构
[1] SANTA CLARA VALLEY MED CTR,DIV INFECT DIS,DEPT MED,SAN JOSE,CA 95128
[2] CALIF INST MED RES,SAN JOSE,COSTA RICA
[3] STANFORD UNIV,SCH MED,STANFORD,CA 94305
关键词
D O I
10.1093/infdis/172.6.1620
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Possible synergy between fluconazole and monocyte-derived macrophages (MDM) for significant killing of Candida species and between fluconazole and monocytes for increased candidacidal activity were studied, Human serum in test medium (RPMI 1640 with 10% fresh autologous human serum) was highly fungistatic for Candida species. Fluconazole in test medium, even at high concentrations, was not fungicidal, Monocytes alone were fungicidal for all Candida species and synergized with fluconazole for increased killing of a fluconazole-sensitive and a fluconazole-resistant Candida albicans isolate, MDM obtained by culturing for 3 or 5 days were not significantly fungicidal for C. albicans but could synergize with fungistatic fluconazole for significant killing, MDM alone killed Candida krusei and Candida glabrata but did not synergize with fluconazole for significantly increased killing, These results, which demonstrate synergy of fluconazole and mononuclear phagocytes for killing, help explain the in vivo efficacy of fluconazole against candidiasis.
引用
收藏
页码:1620 / 1623
页数:4
相关论文
共 15 条
[1]  
BENNETT J, 1990, FLUCONAZOLE OVERVIEW
[2]   MACROPHAGE-COLONY-STIMULATING FACTOR INDUCTION OF ENHANCED MACROPHAGE ANTICRYPTOCOCCAL ACTIVITY - SYNERGY WITH FLUCONAZOLE FOR KILLING [J].
BRUMMER, E ;
STEVENS, DA .
JOURNAL OF INFECTIOUS DISEASES, 1994, 170 (01) :173-179
[3]   ELECTRON MICROSCOPIC STUDIES OF NORMAL AND ABNORMAL ELASTIC FIBERS OF SKIN [J].
HASHIMOT.K ;
DIBELLA, RJ .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1967, 48 (05) :405-&
[4]  
FEUER A, 1990, ARZNEIMITTEL-FORSCH, V40, P1044
[5]   MULTICENTER EVALUATION OF A BROTH MACRODILUTION ANTIFUNGAL SUSCEPTIBILITY TEST FOR YEASTS [J].
FROMTLING, RA ;
GALGIANI, JN ;
PFALLER, MA ;
ESPINELINGROFF, A ;
BARTIZAL, KF ;
BARTLETT, MS ;
BODY, BA ;
FREY, C ;
HALL, G ;
ROBERTS, GD ;
NOLTE, FB ;
ODDS, FC ;
RINALDI, MG ;
SUGAR, AM ;
VILLAREAL, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (01) :39-45
[6]   HUMAN MYCOSES - DRUGS AND TARGETS FOR EMERGING PATHOGENS [J].
GEORGOPAPADAKOU, NH ;
WALSH, TJ .
SCIENCE, 1994, 264 (5157) :371-373
[7]  
LEHRER R I, 1970, Infection and Immunity, V2, P42
[8]  
MORDIN L, 1991, J IMMUNOL, V146, P2790
[9]   ACTIVITY OF FLUCONAZOLE (UK-49,858) AND KETOCONAZOLE AGAINST CANDIDA-ALBICANS INVITRO AND INVIVO [J].
ROGERS, TE ;
GALGIANI, JN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 30 (03) :418-422
[10]   CANDIDA-KRUSEI - BIOLOGY, EPIDEMIOLOGY, PATHOGENICITY AND CLINICAL MANIFESTATIONS OF AN EMERGING PATHOGEN [J].
SAMARANAYAKE, YH ;
SAMARANAYAKE, LP .
JOURNAL OF MEDICAL MICROBIOLOGY, 1994, 41 (05) :295-310